Pharma BD Deal Intelligence

Takeda Pharmaceutical Company Ltd. / Insilico Medicine Inc.

2026 · Co-Development · $600M · Complete

AI-native discovery collaboration extending Takeda's early pipeline

Takeda and Insilico Medicine formed a strategic AI drug-discovery collaboration under which Insilico applies its Pharma.AI platform to identify clinically differentiated candidates against targets across Takeda's therapeutic areas; Takeda advances selected molecules through clinical development. Insilico receives approximately $60 million in project-initiation fees and near-term payments, with total consideration potentially reaching approximately $600 million through success-based milestones plus tiered royalties. The deal supports Takeda's transition to an AI-native discovery model.

Key facts

Announced Jul 02, 2026
Deal value $600M
Deal type Co-Development
Therapeutic area Multiple (undisclosed)

Related deals — scored

Deal	Year	Value	Outcome
Takeda Pharmaceutical Company Ltd. / Insilico Medicine Inc. (this deal)	2026	$600M	54
Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi	2022	$6.0B	82
Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals	2003	$8.8B	82
Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals	2003	$5.2B	77
Takeda Pharmaceutical Company Ltd. / Nycomed	2011	$13.7B	72
Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals	2008	$8.8B	68
Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc.	2018	$1.2B	64

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2026 deals · Takeda Pharmaceutical Company Ltd. deals · Multiple (undisclosed) deals